Moderna Sinks 7% as Traders Book Profits on a 392% Year-to-Date Surge; BioNTech Drops 4%, Merck Slips

David Moadel

Mon, August 24, 2026 at 6:34 PM GMT+3 5 min read

Quick Read

MRNA drops 7% to $135 after a 392% YTD surge, as traders book profits with no new negative catalysts driving the decline.
Partner MRK gained 47% YTD on Keytruda's label expansion potential, while BNTX trails at 22% amid a slower oncology pivot and Moderna patent litigation.
Moderna's intismeran combined with Keytruda became the first positive phase 3 for an mRNA-based cancer therapy, targeting 112,000 new U.S. melanoma cases annually.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Merck didn't make the cut. Grab the names FREE today.

Moderna (NASDAQ:MRNA) stock is down 7% to $135.22 in Monday morning trading, cooling off after one of the most explosive runs in biotech this year. The pullback follows a vertical ascent that carried shares to a record high of $176.66 during last week's advance. Volume has been heavy since the opening bell as short-term traders lock in gains.

gorodenkoff / iStock via Getty Images

The give-back looks orderly. Moderna stock was up 392% year to date (YTD) through Friday's close, so a single-session dip of this size still leaves the run largely intact. That proportion is the story here. For context, the iShares Biotechnology ETF (NASDAQ:IBB) is down 1% to $211.73.

MRNA Price Target — 24/7 Wall St.

Reddit sentiment on Moderna remained very bullish through the weekend even as the drawdown developed, suggesting the retail base has not turned. Institutional positioning is the swing factor.

Profit-Taking, Not a New Catalyst

No new company announcement, trial update, regulatory action or analyst downgrade has been reported today. The phase 3 melanoma data that fueled the rally is unchanged, and Moderna hasn't disclosed material news since its July 31 second-quarter report. Traders are simply booking gains after a parabolic move.

Options positioning reinforces the read. The put-call ratio across Moderna's full chain sits at 1.06, with heavier hedging visible in longer-dated 2027 expirations. That skew is consistent with holders locking in profits and buying downside protection.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Merck didn't make the cut. Grab the names FREE today.

Melanoma Data Still Anchors the Bull Case

The catalyst behind the rally remains intact. Moderna's intismeran autogene, an mRNA-based individualized neoantigen therapy, was tested in combination with Merck's (NYSE:MRK) Keytruda in a late-stage melanoma trial, and at a pre-specified interim analysis the combination met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival.

The trial enrolled patients with completely resected stage IIB, IIC, III or IV cutaneous melanoma who had not received prior systemic therapy. Merck shares are down 1% to $150.61 this morning.

For Moderna, the readout was the first positive phase 3 for an individualized neoantigen therapy and for an mRNA-based cancer therapy, and the first phase 3 to show a clinically meaningful improvement over Keytruda alone. Safety profiles were generally positive with no new safety signals, and the study continues to evaluate overall survival.

The commercial opportunity is substantial. The U.S. is expected to register 112,000 new melanoma cases this year with 8,500 deaths, and roughly 330,000 cases were diagnosed globally in 2022. A cancer indication of this size explains why the market repriced Moderna's oncology pipeline in a matter of days.

Additional pipeline catalysts remain on deck. Registrational data from Moderna's propionic acidemia program and continued follow-up across the intismeran oncology franchise in bladder cancer, non-small cell lung cancer and renal cell carcinoma are all expected. That optionality is a meaningful part of what the recent rally has been discounting.

Peers Along for the Ride

Merck, Moderna's partner on the intismeran program, has ridden the same wave from a different starting point. Merck stock was up 47% year to date through Friday's close, supported by the Keytruda franchise and the melanoma combination's implications for label expansion.

BioNTech (NASDAQ:BNTX), the other high-profile mRNA name, has lagged the Moderna stock surge. BioNTech stock was up 22% year to date through Friday's close, reflecting a slower oncology pivot and ongoing patent litigation with Moderna. This morning, BNTX shares are down 4% to $111.47. Neither peer carries a comparable session move today, which underscores the Moderna-specific stock unwind.

What Investors Should Watch Next

For investors sitting on paper gains, this is the moment to think about position sizing in Moderna. A 7% single-day pullback against a triple-digit YTD run is small in proportion, though sharp moves in both directions tend to cluster around parabolic stocks (we made the case for riding a mania while planning the exit in a free handbook here: The Bubble Survivor's Handbook). Trimming into strength and setting explicit downside levels should keep exposure manageable.

New entrants should be especially cautious. Moderna still posts material losses, with a Q2 net loss of $782 million on revenue of $145 million. The business remains dependent on pipeline execution to justify its current market capitalization, so sizing any new position modestly should keep drawdown risk in check given the volatility profile.

MRNA Earnings Explorer — 24/7 Wall St.

Social sentiment has amplified the swings. Moderna has drawn heavy attention on Reddit's WallStreetBets forum, with one high-profile MRNA post drawing 4,995 upvotes and 484 comments. Retail flow of that character tends to accelerate moves in both directions, which argues for tighter risk controls on any fresh entry.

Keep an eye on Moderna stock into the close for a read on whether buyers step back in near the $130 area. Any read-through commentary on the intismeran overall-survival follow-up could shape follow-through direction. Absent a fresh headline, today's action is a positioning event rather than a thesis change.